Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
Abstract Identifying molecular features is an essential component of the management and targeted therapy of brain metastases (BMs). The molecular features are different between primary lung cancers and BMs of lung cancer. Here we report the DNA and RNA mutational profiles of 43 pathological samples of BMs. In addition to previously reported mutational events associated with targeted therapy, PTPRZ1‐MET, which was previously exclusively identified in glioma, was present in two cases of BMs of lung cancer. Furthermore, MET exon 14 skipping may be more common (6/37 cases) in BMs of lung cancer than the frequency previously reported in lung cancer. These findings highlight the clinical significance of targeted DNA plus RNA sequencing for BMs and suggest PTPRZ1‐MET and MET exon 14 skipping as critical molecular events that may serve as targets of targeted therapy in BMs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Cancer Science - 113(2022), 2, Seite 796-801 |
| Beteiligte Personen: |
Chai, Rui‐Chao [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Japanese Cancer Association |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/cas.15211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003090981 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003090981 | ||
| 003 | DE-627 | ||
| 005 | 20230307123807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/cas.15211 |2 doi | |
| 028 | 5 | 2 | |a CAS_CAS15211.xml |
| 035 | |a (DE-627)WLY003090981 | ||
| 035 | |a (WILEY)CAS15211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Chai, Rui‐Chao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases |
| 264 | 1 | |c 2022 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Japanese Cancer Association | ||
| 520 | |a Abstract Identifying molecular features is an essential component of the management and targeted therapy of brain metastases (BMs). The molecular features are different between primary lung cancers and BMs of lung cancer. Here we report the DNA and RNA mutational profiles of 43 pathological samples of BMs. In addition to previously reported mutational events associated with targeted therapy, PTPRZ1‐MET, which was previously exclusively identified in glioma, was present in two cases of BMs of lung cancer. Furthermore, MET exon 14 skipping may be more common (6/37 cases) in BMs of lung cancer than the frequency previously reported in lung cancer. These findings highlight the clinical significance of targeted DNA plus RNA sequencing for BMs and suggest PTPRZ1‐MET and MET exon 14 skipping as critical molecular events that may serve as targets of targeted therapy in BMs. | ||
| 700 | 1 | |a Liu, Xing |4 aut | |
| 700 | 1 | |a Pang, Bo |4 aut | |
| 700 | 1 | |a Liu, Yu‐Qing |4 aut | |
| 700 | 1 | |a Li, Jing‐Jun |4 aut | |
| 700 | 1 | |a Li, Yang‐Fang |4 aut | |
| 700 | 1 | |a Zhao, Zheng |4 aut | |
| 700 | 1 | |a Du, Jiang |4 aut | |
| 700 | 1 | |a Bao, Zhao Shi |4 aut | |
| 700 | 1 | |a Jiang, Tao |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer Science |g 113(2022), 2, Seite 796-801 |w (DE-627)WLY003074986 |x 13497006 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2022 |g number:2 |g pages:796-801 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.81 |q ASE |
| 951 | |a AR | ||
| 952 | |d 113 |j 2022 |e 2 |h 796-801 |g 6 | ||